Press Releases – VYNE Therapeutics

VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

May, 18 2022

BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at the HC Wainwright & Co. Global Investment Conference on May 25, 2022. Management will also be available for one-on-one meetings with investors. HC Wainwright & Co. Global Investment Conference – Presentation Details Date: Wednesday, May 25, 2022 Time: 9:00 a.m. ET Webcast Link: https://journey.ct.events/view/f49ba6f9-4835-4fb5-9a1c-0c341c71da26 *a replay will be…

Post date May 18, 2022

VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May, 12 2022

Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to host KOL webinar on InhiBETTM BET inhibitor platform on May 17th BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the quarter ended March 31, 2022 and provided a business update. “VYNE made significant progress in the first quarter of 2022 with our pipeline of novel programs…

Post date May 12, 2022

VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform

May, 10 2022

BRIDGEWATER, N.J., May 10, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it will hold a virtual Key Opinion Leader (KOL) event on VYNE’s InhiBET™ BET Inhibitor Platform on Tuesday, May 17, 2022 at 10:00 a.m. ET. The agenda for the webinar will include an overview on pan-bromodomain and extra-terminal (“BET”) inhibition for the treatment of various immuno-inflammatory conditions, a review of the current treatment landscape and unmet medical need in treating patients with vitiligo, a discussion…

Post date May 10, 2022

VYNE Therapeutics to Present at LifeSci Partners’ Immunology & Inflammation Symposium on May 10th

May, 06 2022

BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at LifeSci Partners’ virtual Immunology and Inflammation Symposium, taking place May 10th-11th, 2022. Virtual Presentation Details Date: Tuesday, May 10th Time: 1:30pm Eastern Time Webcast Link: VYNE Therapeutics Presentation The replay of the webcast will be available on the VYNE website for 90 days following the conference. About VYNE…

Post date May 6, 2022

VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

April, 07 2022

At week 2, FMX114 demonstrated a statistically significant reduction in both absolute and percent change in ADSI score compared to vehicle Phase 2a safety and efficacy results expected in the second quarter BRIDGEWATER, N.J., April 07, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive efficacy results from the Phase 1b segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (“AD”). FMX114 is VYNE’s proprietary investigational combination gel formulation of tofacitinib…

Post date April 7, 2022

VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis

March, 30 2022

VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg doses VYN201 also demonstrated numerically superior results at 1mg/kg and 10mg/kg doses compared to leading injectable steroid, dexamethasone, in inhibiting inflammation in arthritic joints of mice Data supports potential broad utility of VYN201 as a potent anti-inflammatory molecule delivered across multiple dosage forms BRIDGEWATER, N.J., March 30, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced positive preclinical data in a rheumatoid arthritis…

Post date March 30, 2022

Subscribe